At a glance
ClinicalIndex Comparison RecordN/ACompleted· 39 enrolled
Drug / intervention
Methylprednisolonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of 4.5 Gram Methylprednisolone Administered Once Weekly for 12 Weeks on Bone Metabolism in Graves´ Ophthalmopathy
In Brief
An observational study evaluating Methylprednisolone for Graves Ophthalmopathy. Completed, enrolled 39 participants across 2 sites.
Detailed Summary
Continuous use of systemic glucocorticoids decreases bone mineral density and increases fracture risk. Graves' orbitopathy is treated with weekly infusion of high-dose intravenous glucocorticoid. The investigators aim at investigating whether this treatment regimen also affects bone metabolism.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGraves Ophthalmopathy
CountriesDenmark
CollaboratorsOdense University Hospital
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartJun 2017
Primary CompletionJul 2022
Study CompletionFeb 2024
TodayJul 2026
First PostedApr 21, 2017
Enrollment StartJun 7, 2017
Primary CompletionJul 14, 2022
Study CompletionFeb 1, 2024
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 9.2 years ago
Interventions
Methylprednisolonedrug
Intravenous methylprednisolone